2-Amino-3-methylcarboxy-5-heptyl-thiophene (TJ191) is a selective anti-cancer small molecule that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells

Oncotarget
Ahmed El-GazzarS Liekens

Abstract

Current chemotherapy regimens often include non-specific cytostatic/cytotoxic drugs, which do not distinguish between normal and tumor cells, therefore causing considerable systemic toxicity. We previously reported the synthesis and anti-proliferative activity of a novel synthetic 2-aminothiophene-3-carboxylic acid ester derivative TJ191 that selectively targets certain cancer cells without affecting the proliferation of other cancer cells or normal fibroblasts or immune cells (over 600-fold selectivity). In a panel of ten human T-cell leukemia/lymphoma cell lines and peripheral blood mononuclear cells (PBMCs), we now found that transforming growth factor β type III receptor (TβRIII) expression correlates inversely with TJ191 sensitivity, but not with sensitivity against classical chemotherapeutic drugs, thus serving as a predictive marker for TJ191 sensitivity. Accordingly, CRISPR/Cas9-mediated knock-out of TβRIII partially restored the susceptibility of TJ191-resistant cells to this novel compound. Our findings highlight TJ191 as a potent and selective anti-cancer molecule with pronounced activity against human malignant T-cells expressing low levels of TβRIII.

References

Jun 18, 2003·Cell·Yigong Shi, Joan Massagué
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rebecca L Elliott, Gerard C Blobe
Jun 24, 2006·Nature Reviews. Cancer·Brian Bierie, Harold L Moses
Aug 18, 2006·Journal of Medicinal Chemistry·Carlos García-AparicioSonsoles Velazquez
Sep 23, 2006·Nature Reviews. Cancer·Robert H Shoemaker
Dec 13, 2006·The Journal of Clinical Investigation·Mei DongGerard C Blobe
Jan 5, 2008·Carcinogenesis·Elizabeth C FingerGerard C Blobe
Nov 1, 2008·Cancer Research·Vincent T DeVita, Edward Chu
Feb 22, 2011·Journal of Medicinal Chemistry·Alberto Diez-TorrubiaSonsoles Velázquez
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Sep 25, 2012·Nature Reviews. Drug Discovery·Rosemary J Akhurst, Akiko Hata
Sep 26, 2013·Nature Reviews. Cancer·Caitriona HolohanPatrick G Johnston
Oct 8, 2014·Nature Reviews. Clinical Oncology·James H Doroshow, Shivaani Kummar
May 26, 2016·Oncotarget·María-Dolores CanelaSandra Liekens
Apr 4, 2017·European Journal of Medicinal Chemistry·Joice ThomasJan Balzarini

❮ Previous
Next ❯

Methods Mentioned

BETA
fluorescence microscopy
flow cytometry
Fluorescence
PCR
RNA-seq
transfection

Software Mentioned

7500
BD Diva

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.